Frist Affiliated Hospital of Kunming Medical University Trials

Frist Affiliated Hospital of Kunming Medical University	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Yang, Bin

NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Completed

336

Canada, RoW

Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2

Reistone Biopharma Company Limited

Atopic Dermatitis

08/22

05/23

NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Active, not recruiting

330

RoW

SHR0302, Placebo

Reistone Biopharma Company Limited

Alopecia Areata

10/23

02/24

TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting

1300

Europe, Canada, Japan, US, RoW

TAK-279

Takeda

Plaque Psoriasis

05/26

TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Recruiting

518

RoW

TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non-small Cell Lung Cancer

08/25

12/25

NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting

693

Europe, Canada, Japan, US, RoW

TAK-279, Placebo, Apremilast

Takeda

Plaque Psoriasis

08/25

04/26

PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Recruiting

600

Europe, Canada, US, RoW

Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere

OncoC4, Inc., BioNTech SE

Non Small Cell Lung Cancer

06/26

06/27

MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Active, not recruiting

2/3

645

RoW

SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo

Reistone Biopharma Company Limited

Atopic Dermatitis

09/23

07/24

BK2016.01, NCT03146637: Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Recruiting

RoW

Activated CIK, CIK

Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital

Advanced Liver Cancer

01/21

CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Jan 2022 - Jun 2022 : Interim data from CAPSTONE trial for NSCLC

Recruiting

RoW

Camrelizumab, SHR-1210, Famitinib, SHR-1020

Qian Chu, Jiangsu HengRui Medicine Co., Ltd.

Sarcomatoid Carcinoma of Lung

12/24

06/25

SSGJ-611-AD-II-01, NCT05544591: Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

Completed

RoW

611 Q2W, 611 Q4W, Matching placebo, placebo

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Dermatitis, Atopic

07/23

09/23

NCT06228560: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Recruiting

200

RoW

LP-003, Placebo, Omalizumab

Longbio Pharma

Chronic Spontaneous Urticaria

01/25

NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Recruiting

160

RoW

TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Atopic Dermatitis

03/24

AtDvance, NCT06447506: Long-Term Study () to Evaluate GSK1070806 in Atopic Dermatitis.

Active, not recruiting

Europe, Canada, Japan, US, RoW

GSK1070806

GlaxoSmithKline

Dermatitis, Atopic

07/25

NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

Active, not recruiting

163

Europe, Canada, Japan, US, RoW

GSK1070806, Placebo

GlaxoSmithKline

Dermatitis, Atopic

10/25

01/26

NCT06951646: ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Not yet recruiting

RoW

Ivonescimab plus docetaxel, Standard Treatment

Second Xiangya Hospital of Central South University, Akeso-Sino Pharma Co., Ltd., Nanjing Shihejiyin Technology, Inc.

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)

07/28

06/30

SKB264-II-04, NCT05816252: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer () (MK-2870-003)

Recruiting

498

Europe, RoW

SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT), Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate

Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Non-small Cell Lung Cancer

12/25

10/26

NCT05713110: A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Recruiting

140

RoW

tazemetostat, HMPL-689

Hutchmed

Relapsed/Refractory Lymphoma

05/26

12/26

NCT04908046: A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

Completed

RoW

HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .

Hutchmed

Advanced Malignant Solid Tumors

01/24

02/24

NCT06433531: A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)

Recruiting

RoW

TQH2929 Injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Generalized Pustular Psoriasis

02/25

NCT05886374: A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

Recruiting

RoW

HMPL-415S1

Hutchmed

Advanced Malignant Solid Tumors

05/25

06/26

NCT06365697: Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis

Active, not recruiting

N/A

188

RoW

Ton-bridge carotid stent, WALLSTENT carotid stent

Zhuhai Tonbridge Medical Tech. Co., Ltd.

Carotid Artery Stenosis

12/24

10/25

NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting

N/A

184

RoW

Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter

Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

Coronary Artery Disease, Intravascular Lithotripsy

12/24

09/25

NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting

N/A

2150

RoW

Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy

Lepu Medical Technology (Beijing) Co., Ltd.

Coronary Heart Disease

01/26

01/28

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Yang, Bin

NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Completed

336

Canada, RoW

Reistone Biopharma Company Limited

Atopic Dermatitis

08/22

05/23

NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Active, not recruiting

330

RoW

SHR0302, Placebo

Reistone Biopharma Company Limited

Alopecia Areata

10/23

02/24

TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting

1300

Europe, Canada, Japan, US, RoW

TAK-279

Takeda

Plaque Psoriasis

05/26

Recruiting

518

RoW

TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non-small Cell Lung Cancer

08/25

12/25

NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting

693

Europe, Canada, Japan, US, RoW

TAK-279, Placebo, Apremilast

Takeda

Plaque Psoriasis

08/25

04/26

PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Recruiting

600

Europe, Canada, US, RoW

Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere

OncoC4, Inc., BioNTech SE

Non Small Cell Lung Cancer

06/26

06/27

MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Active, not recruiting

2/3

645

RoW

SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo

Reistone Biopharma Company Limited

Atopic Dermatitis

09/23

07/24

BK2016.01, NCT03146637: Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Recruiting

RoW

Activated CIK, CIK

Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital

Advanced Liver Cancer

01/21

CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Jan 2022 - Jun 2022 : Interim data from CAPSTONE trial for NSCLC

Recruiting

RoW

Camrelizumab, SHR-1210, Famitinib, SHR-1020

Qian Chu, Jiangsu HengRui Medicine Co., Ltd.

Sarcomatoid Carcinoma of Lung

12/24

06/25

SSGJ-611-AD-II-01, NCT05544591: Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

Completed

RoW

611 Q2W, 611 Q4W, Matching placebo, placebo

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Dermatitis, Atopic

07/23

09/23

NCT06228560: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Recruiting

200

RoW

LP-003, Placebo, Omalizumab

Longbio Pharma

Chronic Spontaneous Urticaria

01/25

NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Recruiting

160

RoW

TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Atopic Dermatitis

03/24

AtDvance, NCT06447506: Long-Term Study () to Evaluate GSK1070806 in Atopic Dermatitis.

Active, not recruiting

Europe, Canada, Japan, US, RoW

GSK1070806

GlaxoSmithKline

Dermatitis, Atopic

07/25

NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

Active, not recruiting

163

Europe, Canada, Japan, US, RoW

GSK1070806, Placebo

GlaxoSmithKline

Dermatitis, Atopic

10/25

01/26

NCT06951646: ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Not yet recruiting

RoW

Ivonescimab plus docetaxel, Standard Treatment

Second Xiangya Hospital of Central South University, Akeso-Sino Pharma Co., Ltd., Nanjing Shihejiyin Technology, Inc.

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)

07/28

06/30

SKB264-II-04, NCT05816252: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer () (MK-2870-003)

Recruiting

498

Europe, RoW

SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT), Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate

Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Non-small Cell Lung Cancer

12/25

10/26

NCT05713110: A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Recruiting

140

RoW

tazemetostat, HMPL-689

Hutchmed

Relapsed/Refractory Lymphoma

05/26

12/26

NCT04908046: A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

Completed

RoW

HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .

Hutchmed

Advanced Malignant Solid Tumors

01/24

02/24

NCT06433531: A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)

Recruiting

RoW

TQH2929 Injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Generalized Pustular Psoriasis

02/25

NCT05886374: A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

Recruiting

RoW

HMPL-415S1

Hutchmed

Advanced Malignant Solid Tumors

05/25

06/26

NCT06365697: Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis

Active, not recruiting

N/A

188

RoW

Ton-bridge carotid stent, WALLSTENT carotid stent

Zhuhai Tonbridge Medical Tech. Co., Ltd.

Carotid Artery Stenosis

12/24

10/25

NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting

N/A

184

RoW

Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter

Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

Coronary Artery Disease, Intravascular Lithotripsy

12/24

09/25

NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting

N/A

2150

RoW

Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy

Lepu Medical Technology (Beijing) Co., Ltd.

Coronary Heart Disease

01/26

01/28



	Diseases Companies Products Productz Mechanisms of Action Sites